Anticancer Effect of Metformin in Herceptin-Conjugated Liposome for Breast Canceropen access
- Authors
- Lee, Ji-Yeon; Shin, Dae Hwan; Kim, Jin-Seok
- Issue Date
- Jan-2020
- Publisher
- MDPI
- Keywords
- Metformin; Herceptin; breast cancer stem cell; liposome; targeting
- Citation
- PHARMACEUTICS, v.12, no.1
- Journal Title
- PHARMACEUTICS
- Volume
- 12
- Number
- 1
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/2560
- DOI
- 10.3390/pharmaceutics12010011
- ISSN
- 1999-4923
1999-4923
- Abstract
- Metformin (MET) is an anti-diabetic drug effective against breast cancer, targeting breast cancer stem cells (BCSCs). MET-encapsulating liposome (LP-MET) and Herceptin-conjugated LP-MET (Her-LP-MET) were evaluated for their anti-cancer effect in vitro and in vivo. Size and zeta potentials of LP-MET and Her-LP-MET were suitable for enhanced permeability and retention effects. Her-LP-MET yielded greater inhibition of BCSC proliferation in vitro than free MET or LP-MET, as well as a dose-dependent long-term anti-proliferation effect. Further, the anti-migration effect of Her-LP-MET on BCSCs was superior to that of MET or LP-MET, and was enhanced when used in concert with doxorubicin (DOX). In a mouse model, Her-LP-MET combined with free DOX was more effective than free MET, free DOX, or Her-LP-MET. Moreover, Her-LP-MET combined with free DOX yielded tumor remission, whereas free DOX alone resulted in metastasis or death. As such, Her-LP-MET formulation is expected to provide a new therapeutic modality targeting BCSCs.
- Files in This Item
-
Go to Link
- Appears in
Collections - 약학대학 > 약학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.